Loading...
12/15 12:58
Loading...
| Name | Price | Today | Market Cap | Event Catalyst |
|---|---|---|---|---|
| $7.42 | +173.80% | 57.10M | -- | |
| $11.27 | +164.46% | 33.58M | Positive clinical trial results for RAD 101 significantly boosted investor confidence and stock price. | |
| $5.07 | +53.64% | 81.00M | 3 E Network Technology Group's AI data center agreement significantly boosted sector sentiment and ARTV's stock price. | |
| $4.31 | +38.14% | 14.05M | -- | |
| $3.51 | +34.29% | 113.39M | -- | |
| $3.99 | +33.00% | 204.55M | Promising data for key drug candidates boosts investor sentiment and stock price. | |
| $4.36 | +31.33% | 3.02M | -- | |
| $11.25 | +28.12% | 384.53M | Upcoming webcast to review positive Phase 2 trial results for KYV-101 enhances market potential. | |
| $0.86 | +26.97% | 14.95M | -- | |
| $23.95 | +22.38% | 1.79B | Immunome's stock rose due to positive trial results and upcoming FDA application for Varegacestat. | |
| $5.70 | +20.00% | 3.24M | -- | |
| $3.03 | +19.76% | 37.84M | -- | |
| $1.67 | +18.44% | 163.60M | -- | |
| $5.68 | +18.29% | 66.62M | Beneficient's stock surged due to positive trial results from peers like Kyverna Therapeutics. | |
| $2.72 | +18.26% | 79.22M | -- | |
| $0.40 | +16.23% | 26.22M | -- | |
| $1.12 | +14.95% | 11.66M | -- | |
| $3.25 | +14.84% | 70.75M | -- | |
| $0.70 | +14.40% | 70.02M | -- | |
| $1.21 | +13.68% | 60.32M | -- | |
| $3.33 | +13.65% | 90.94M | FDA accepted Fortress Biotech's NDA for CUTX-101, boosting market prospects for Menkes disease treatment. | |
| $9.50 | +13.37% | 33.90M | FibroGen's roxadustat received FDA Orphan Drug Designation, boosting its stock price significantly. | |
| $1.36 | +13.33% | 10.70M | cbdMD Inc. shares surged 126% after compliance news, boosting sector sentiment. | |
| $17.12 | +13.12% | 470.03M | -- | |
| $1.68 | +12.75% | 34.92M | -- | |
| $12.65 | +12.44% | 1.49B | -- | |
| $1.82 | +12.35% | 24.49M | CIMG Inc. signed a $106.5 million contract, boosting market confidence and growth potential. | |
| $1.82 | +12.35% | 47.46M | -- | |
| $1.92 | +12.28% | 107.50M | -- | |
| $1.71 | +12.17% | 104.10M | -- | |
| $3.14 | +12.14% | 352.83M | Positive news from sector peers boosted sentiment and contributed to NBY's stock price increase. | |
| $2.31 | +12.14% | 141.53M | -- | |
| $21.35 | +11.72% | 238.88M | -- | |
| $3.34 | +11.33% | 39.56M | -- | |
| $8.43 | +11.21% | 47.96M | -- | |
| $4.04 | +11.14% | 6.45M | -- | |
| $5.38 | +10.93% | 137.02M | -- | |
| $3.22 | +10.65% | 106.77M | -- | |
| $0.99 | +10.42% | 28.96M | -- | |
| $2.18 | +10.10% | 87.95M | -- | |
| $12.11 | +10.09% | 22.83M | -- | |
| $14.11 | +9.81% | 601.94M | -- | |
| $4.50 | +9.76% | 11.97M | -- | |
| $4.35 | +9.60% | 1.27B | -- | |
| $7.28 | +9.47% | 222.05M | -- | |
| $13.67 | +9.27% | 274.10M | -- | |
| $0.85 | +9.12% | 110.02M | -- | |
| $8.45 | +9.03% | 791.17M | -- | |
| $1.22 | +8.48% | 28.81M | -- | |
| $9.26 | +8.43% | 323.00M | -- |
